title: Treatment of tuberculosis in HIV-infected patients: safety and antiretroviral efficacy of the concomitant use of ritonavir and rifampin.
authors: Department of Infectious Diseases Hospital Ramón y Cajal, Madrid, Spain.
authors: S
authors: S
authors: Moreno
authors: D
authors: D
authors: Podzamczer
authors: R
authors: R
authors: Blázquez
authors: J A
authors: JA
authors: Iribarren
authors: E
authors: E
authors: Ferrer
authors: J
authors: J
authors: Reparaz
authors: J M
authors: JM
authors: Peña
authors: E
authors: E
authors: Cabrero
authors: L
authors: L
authors: Usán
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D000328:Adult; D000904:Antibiotics, Antitubercular / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D003257:Consumer Product Safety; D004359:Drug Therapy, Combination; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000254:growth & development; D006801:Humans; D010865:Pilot Projects; D011718:Pyrazinamide / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D012293:Rifampin / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D019438:Ritonavir / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D014376:Tuberculosis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D019562:Viral Load
chemical_list: D000904:Antibiotics, Antitubercular; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D011718:Pyrazinamide; D019438:Ritonavir; D012293:Rifampin